<DOC>
	<DOCNO>NCT02914600</DOCNO>
	<brief_summary>The primary objective study observe long-term safety filgotinib adult complete meet protocol specify efficacy discontinuation criterion prior Gilead-sponsored filgotinib treatment study Crohn 's disease ( CD ) .</brief_summary>
	<brief_title>Filgotinib Long-Term Extension Study Adults With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Must ability understand sign write informed consent form ( ICF ) , must obtain prior initiation study procedure associate trial Must meet eligibility criterion Gileadsponsored CD parent protocol Females childbearing potential must negative pregnancy test Day 1 Males female childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception describe study protocol , duration describe Willingness refrain live attenuate vaccine study 12 week last dose study drug Key Known hypersensitivity study drug Any chronic medical condition ( include , limited , cardiac pulmonary disease , alcohol drug abuse ) , opinion Investigator , would make individual unsuitable study would prevent compliance study protocol Males females reproductive potential unwilling abide protocolspecified contraceptive method define study protocol Use prohibit medication outline study protocol NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>